Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring.

Taguchi T, Kimura K, Tsuji S, Ito S, Takamura S, Shimotatara H, Shimizu N, Kubo H, Hoshiyama A, Hayashi A, Takano K, Miyatsuka T

Journal of the Endocrine Society29 Nov 2025

PMID41472888PMCIDPMC12745729DOI10.1210/jendso/bvaf193PepBankPUB-41472888

Download PDF PubMedAsk about this study

Jump to 5 results

Summary

ContextSomapacitan, a long-acting GH derivative, has been used to treat adult GH deficiency. Although the distinct pharmacokinetics of somapacitan compared with daily GH administration are presumed to affect daily and weekly glucose profiles, detailed information on glucose fluctuations remains limited.ObjectiveGlycemic variability in individuals during somapacitan treatment was assessed.MethodsA prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes. Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD. Continuous glucose monitoring was performed for 14 days before and after the switch. The primary endpoint was the change in glycemic variability indices.ResultsWith IGF-1 levels matched between regimens, no significant differences were observed in glycated hemoglobin A1c, fasting blood glucose, and insulin resistance index before and after switching to somapacitan. The continuous glucose monitoring data demonstrated that the mean sensor glucose level (SGL) and continuous overall net glycemic action over 24 hours were significantly increased during somapacitan treatment. Notably, whereas SGLs showed no significant interday fluctuations during somatropin treatment, biphasic glucose fluctuations were observed during somapacitan treatment, with mean SGLs peaking on the second day and reaching their lowest on the fourth day. After switching to somapacitan, the time below range tended to decrease across all days.ConclusionThe switch from somatropin to somapacitan resulted in increased interday glucose variability, characterized by biphasic glucose fluctuations, suggesting a unique physiological effect of somapacitan on glucose profiles.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with GHD without diabetes, HbA1c, fasting glucose, and insulin resistance index did not differ significantly after switching from somatropin to somapacitan.
In plain wordsIn adults with GHD, HbA1c, fasting glucose, and insulin resistance did not differ significantly after switching from somatropin to somapacitan.
Peptide
Somapacitan
Outcome
No significant changeHbA1c, fasting glucose, and insulin resistance index
Study
n = 20
Comparator
Prior somatropin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
With IGF-1 levels matched between regimens, no significant differences were observed in glycated hemoglobin A1c, fasting blood glucose, and insulin resistance index before and after switching to somapacitan.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes.
Summary · context
Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD.
Summary · context
Continuous glucose monitoring was performed for 14 days before and after the switch.
Show in the study text Report a problemFND-4147288801
02HumanNon-randomized trialEfficacy outcome
In adults with GHD without diabetes, mean sensor glucose increased significantly during somapacitan treatment after switching from somatropin.
In plain wordsIn adults with GHD without diabetes, mean sensor glucose increased significantly after switching from somatropin to somapacitan.
Peptide
Somapacitan
Outcome
IncreaseMean sensor glucose level
Study
n = 20
Comparator
Prior somatropin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The continuous glucose monitoring data demonstrated that the mean sensor glucose level (SGL) and continuous overall net glycemic action over 24 hours were significantly increased during somapacitan treatment.
4 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the change in glycemic variability indices.
Summary · context
A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes.
Summary · context
Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD.
Summary · context
Continuous glucose monitoring was performed for 14 days before and after the switch.
Show in the study text Report a problemFND-4147288802
03HumanNon-randomized trialEfficacy outcome
In adults with GHD without diabetes, continuous overall net glycemic action over 24 hours increased significantly after switching from somatropin to somapacitan.
In plain wordsIn adults with GHD, continuous overall net glycemic action over 24 hours increased significantly after switching from somatropin to somapacitan.
Peptide
Somapacitan
Outcome
IncreaseContinuous overall net glycemic action over 24 hours
Study
n = 20
Comparator
Prior somatropin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The continuous glucose monitoring data demonstrated that the mean sensor glucose level (SGL) and continuous overall net glycemic action over 24 hours were significantly increased during somapacitan treatment.
4 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the change in glycemic variability indices.
Summary · context
A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes.
Summary · context
Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD.
Summary · context
Continuous glucose monitoring was performed for 14 days before and after the switch.
Show in the study text Report a problemFND-4147288803
04HumanNon-randomized trialEfficacy outcome
In adults with GHD, somapacitan profiles peaked on the second day and reached their lowest on the fourth, whereas somatropin showed no significant interday fluctuations.
In plain wordsIn adults with GHD, somapacitan showed biphasic glucose fluctuations unlike somatropin, with peaks on the second day and lows on the fourth.
Peptide
Somapacitan
Outcome
MixedInterday sensor glucose pattern
Study
n = 20
Comparator
Prior somatropin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Notably, whereas SGLs showed no significant interday fluctuations during somatropin treatment, biphasic glucose fluctuations were observed during somapacitan treatment, with mean SGLs peaking on the second day and reaching their lowest on the fourth day.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes.
Summary · context
Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD.
Summary · context
Continuous glucose monitoring was performed for 14 days before and after the switch.
Show in the study text Report a problemFND-4147288804
05HumanNon-randomized trialEfficacy outcome
In adults with GHD without diabetes, time below range tended to decrease across all days after switching from somatropin to somapacitan.
In plain wordsIn adults with GHD, time below range tended to decrease across all days after switching from somatropin to somapacitan.
Peptide
Somapacitan
Outcome
DecreaseTime below range
Study
n = 20
Comparator
Prior somatropin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
After switching to somapacitan, the time below range tended to decrease across all days.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes.
Summary · context
Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD.
Summary · context
Continuous glucose monitoring was performed for 14 days before and after the switch.
Show in the study text Report a problemFND-4147288805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring.

Summary

Results from this study5

Version history

Subjects

Publication types

Keywords